Full Press Release Details
INSPIRATM ART100 Completes Usability Study in Boston
Ra'anana, Israel, August 9, 2023 - Inspira Technologies
OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the "Company" or "Inspira Technologies"), a company aiming to
revolutionize acute respiratory care by empowering breathing without lungs, is proud to announce it has completed a Usability Study in
Boston, Massachusetts for its INSPIRA ART100 device.
The Usability Study included U.S. healthcare professionals who participated
in testing and examining the INSPIRA ART100 in a setting designed to consider human factors of the intended users, uses and use environments.
Dagi Ben Noon, Inspira Technologies' Chief Executive Officer,
stated: "We are advancing with the INSPIRA ART100. We plan to take a position in disrupting the medical device industry
with our high-grade technology."
The INSPIRA ART100 is an extracorporeal blood circulation medical device
designed for cardiac and pulmonary support, by providing continuous enrichment of the blood with oxygen and carbon dioxide removal. The
INSPIRA ART100 may be suitable for a wide range of extracorporeal treatments in the ICU and during heart surgery.
About Inspira Technologies OXY B.H.N. Ltd.
Inspira Technologies
has a clear mission to revolutionize acute respiratory care through innovation. Our aim is to develop medical technologies and products
that prevent the need for mechanical ventilation. Empowering breathing without lungs, the flagship INSPIRATM ART500 is designed
to boost blood oxygen saturation levels in a matter of minutes, even as the patient remains awake. We strive to deliver blood circulation
technology alongside AI driven monitoring and analytics to create patient-centric and data-driven solutions that enhance patient outcome
and improve hospital efficiency. Through our continuous efforts, we aim to reshape the future of extracorporeal treatments to create
a better healthcare experience for patients around the world. The Company's products have not yet been tested or used in humans
and have not been approved by any regulatory entity.
For more information, please visit our corporate website:
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking statements
pursuant to U.S. Federal securities laws. These forward-looking statements and their implications are based on the current expectations
of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it
discusses its strategy to develop its products, technology and the INSPIRA ART500 medical device. These forward-looking statements and
their implications are based solely on the current expectations of the Company's management and are subject to a number of factors
and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except
as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements
to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information
about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's
annual report on Form 20-F for the fiscal year ended December 31, 2022 filed with the U.S. Securities and Exchange Commission (the "SEC"),
which is available on the SEC's website, www.sec.gov
Public Relations Manager
Inspira Technologies